Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 1/20 | 0.48 |
| ▸ | PDE2A | O00408 | 3/20 | 0.41 |
| ▸ | KIF11 | P52732 | 4/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.38 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.38 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 2/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31537454 | 0.84 | PDE2A (0.42) | MTORPDE2AKIF11NOTUMPTPN5 | |
| SCHEMBL1529230 | 0.84 | PDE2A (0.42) | MTORPDE2AKIF11NOTUMPTPN5 | |
| SCHEMBL10455048 | 0.83 | ESR1 (0.40) | MTOR | |
| SCHEMBL1755260 | 0.80 | PDE2A (0.46) | PDE2AKIF11NOTUMTAS2R14PTPN5 | |
| SCHEMBL20078800 | 0.79 | ESR1 (0.52) | MTORTSHR | |
| SCHEMBL12203436 | 0.79 | TSHR (0.44) | MTORKIF11MAPTGAATSHR | |
| SCHEMBL7863217 | 0.78 | PTPN5 (0.41) | KIF11NOTUMPTPN5TSHRMAPK1 | |
| SCHEMBL27061386 | 0.76 | ESR1 (0.39) | MTORPDE2ATSHR | |
| Water SCHEMBL27703440 | 0.76 | PDE2A (0.43) | PDE2AKIF11NOTUMTAS2R14PTPN5 | |
| SCHEMBL1859691 | 0.74 | PDE2A (0.50) | PDE2AKIF11NOTUMTAS2R14PTPN5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021216951-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY (US) | 2021-10-28 | — | — | WO | disclosed |
| WO-2020038458-A1 | CLASS OF FUSED RING TRIAZOLE COMPOUND, PREPARATION METHOD, AND USE | 如东凌达生物医药科技有限公司 | 2020-02-27 | — | — | WO | disclosed |
| WO-2019063015-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUND WHICH ACTS AS RORγ INHIBITOR | 正大天晴药业集团股份有限公司 | 2019-04-04 | — | — | WO | disclosed |
| EP-1714961-B1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-12-09 | — | — | EP | disclosed |
| US-7994196-B2 | Indazole compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2007-07-26 | — | — | US | disclosed |
| EP-1714961-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2006-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | CYP3A5, CYP3A43, TP53 | MTOR 2264/4885PDE2A 2888/4885KIF11 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.